AtlantiCare
en Español
 
AboutHealth ServicesHealth ConditionsLocationsEvents & CoursesCommunityWays of Giving
  Search  
 
Health News
Today's Headlines
Health Alerts
Health News Feature
Future of Medicine
Health Observances
Product Recalls
Health Library
Illnesses & Conditions
Drug Guide
FDA Drug Approvals
Medical Tests
Self-Help Resources
Complementary Medicine
Medline Search
Health Topics
Allergies
Asthma
Back Pain
Cancer
Caregiver
Depression
Diabetes
GERD
Heart
Kidney
Men's Health
Orthopedic
Parenting
Patient Safety
Pregnancy
Senior
Stress
Stroke
Weight Mgmt
Women's Health
Healthy Living
Fitness
Nutrition
Mind & Body
Family & Home
Today's Headlines

Health News
Daily articles from HealthDay News: breaking news on health issues, drug approvals and recent discoveries.

FDA Approves Generic Risperdal


Antipsychotic drug prescribed for schizophrenia

TUESDAY, July 1 (HealthDay News) -- The first generic versions of the antipsychotic drug Risperdal (risperidone) were approved Monday by the U.S. Food and Drug Administration.

The generic versions in several strengths will be manufactured by Teva Pharmaceuticals USA. They will have the same boxed warnings as the brand name drug, produced by Janssen Pharmaceuticals.

The so-called "black box" warning cautions that older people with dementia-related psychosis taking this class of drug, called atypical anti-psychotics, are at increased risk of death, the FDA said. These medicines aren't approved to treat dementia-related psychosis, but doctors may legally prescribe them for that purpose under what's called "off-label" use.

"This generic drug approval is another example of the FDA's efforts to increase access to safe and effective generic drugs as soon as the law permits," Gary Buehler, director of the FDA's Office of Generic Drugs, said in a statement.

The brand name drug was first approved in 1993.

More information

The FDA has more about this drug's approval history.

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Health News Provided By:
HealthDay
 
 
Notice of Privacy Practices | | Disclaimer    © 2006 AtlantiCare AtlantiCare Access
 

  Powered by HEALTHvision